Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide in prediabetic patients with end-stage renal disease on dialysis
2014-001778-32Phase 2Terminated
- Sponsor
- Bo Feldt-Rasmussen
- Start
- Jun 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of liraglutide in prediabetes and end-stage kidney disease (ESKD) (2 arms), sponsored by Bo Feldt-Rasmussen. Primary endpoint: Glucose tolerance (AUC for plasma glucose during OGTT at week 26). Started Jun 2014; status: terminated.
02
Drugs
03
Conditions
prediabetesend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2014-001778-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001778-32.